AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34253587 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning DSA probability
Number of subjects: 835
Study 34253587 — intervention group
Group type: COMPARATOR
Intervention: Biopsies classified as no rejection (NR)
Number of subjects: 835
Study 34253595 — intervention group
Group type: EXPERIMENTAL
Intervention: ABBV-744
Number of subjects: 0
Study 34253595 — intervention group
Group type: EXPERIMENTAL
Intervention: ABBV-744 + Venetoclax
Number of subjects: 0
Study 34253595 — intervention group
Group type: COMPARATOR
Intervention: ABBV-075
Number of subjects: 0
Study 34253597 — intervention group
Group type: EXPERIMENTAL
Intervention: KPT-9274-everolimus
Number of subjects: 0
Study 34253597 — intervention group
Group type: COMPARATOR
Intervention: everolimus
Number of subjects: 0
Study 34253733 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV2-hAADC delivered via convection-enhanced delivery (CED) to the bilateral substantia nigra (SN) and ventral tegmental area (VTA) with a total infusion volume of 80 µL per hemisphere.
Number of subjects: 7
Study 34253928 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2-specific CAR T cells via locoregional infusion
Number of subjects: 3
Study 34253928 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 3
Study 34254126 — intervention group
Group type: EXPERIMENTAL
Intervention: Siemens Atellica IM hs-cTnI assay
Number of subjects: 1800
Study 34254126 — intervention group
Group type: COMPARATOR
Intervention: Guideline-recommended application of an established hs-cTnI assay
Number of subjects: 1800
Study 34255063 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-containing supplement initiated prepregnancy and continued through pregnancy
Number of subjects: 137
Study 34255063 — intervention group
Group type: COMPARATOR
Intervention: No use of supplement
Number of subjects: 137
Study 34255078 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytoglycogen (PHY) at 0.5 g·min-1
Number of subjects: 13
Study 34255078 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytoglycogen (PHY) at 1.0 g·min-1
Number of subjects: 13
Study 34255078 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytoglycogen (PHY) at 1.5 g·min-1
Number of subjects: 13
Study 34255078 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytoglycogen (PHY) at 2 g·min-1
Number of subjects: 13
Study 34255140 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory treatment initiated or increased
Number of subjects: 1006
Study 34255140 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment increased
Number of subjects: 1006
Study 34255140 — intervention group
Group type: COMPARATOR
Intervention: Initial PGA score
Number of subjects: 1006
Study 34255140 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory therapy increased
Number of subjects: 1006
Study 34255353 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine 20 mg/m²
Number of subjects: 118
Study 34255535 — intervention group
Group type: EXPERIMENTAL
Intervention: BEMPEG 0.006 mg/kg plus NIVO 360 mg once every 3 weeks for ≤ 2 years
Number of subjects: 41
Study 34255555 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Supplement with Antioxidative Santa Herba Extract
Number of subjects: 0
Study 34255555 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34255642 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation program (n=70, 56 completed the program)
Number of subjects: 140
Study 34255658 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention with human support
Number of subjects: 0
Study 34255658 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple recruitment and retention strategies
Number of subjects: 0
Study 34255722 — intervention group
Group type: EXPERIMENTAL
Intervention: HIPPER intervention consisting of 12 online, interactive modules
Number of subjects: 40
Study 34255722 — intervention group
Group type: COMPARATOR
Intervention: Current standard practice consisting of 2 online educational sessions lasting 2 hours each (webinars)
Number of subjects: 40
Study 34255727 — intervention group
Group type: EXPERIMENTAL
Intervention: VoiceAdapt mobile therapy app, used for 5 weeks of training.
Number of subjects: 80
Study 34255727 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group, no training for 5 weeks followed by 5 weeks of training with VoiceAdapt.
Number of subjects: 80
Study 34255901 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous invariant natural killer T (iNKT) cells
Number of subjects: 10
Study 34255974 — intervention group
Group type: EXPERIMENTAL
Intervention: Shear Wave Elastography
Number of subjects: 0
Study 34256007 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34256279 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisertib 40 mg BID on D1-3 per week plus nab-paclitaxel 100 mg/m²
Number of subjects: 31
Study 34256305 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly AAT augmentation therapy
Number of subjects: 0
Study 34256305 — intervention group
Group type: EXPERIMENTAL
Intervention: Silencing AAT production, improving protein folding and secretion, promoting AAT degradation
Number of subjects: 0
Study 34256732 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung cancer patients receiving immunotherapy
Number of subjects: 34
Study 34256732 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung cancer patients not suffering from irAEs
Number of subjects: 34
Study 34256732 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders to combined chemoimmunotherapy
Number of subjects: 34
Study 34256732 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders to chemoimmunotherapy
Number of subjects: 34
Study 34256732 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal samples from lung cancer patients
Number of subjects: 34
Study 34256732 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 34
Study 34256735 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalized participants
Number of subjects: 119
Study 34256735 — intervention group
Group type: COMPARATOR
Intervention: Non-hospitalized participants
Number of subjects: 119
Study 34256735 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants at 90-174 days post SARS-CoV-2 diagnosis
Number of subjects: 119
Study 34256735 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalized participants at 90-174 days post SARS-CoV-2 diagnosis
Number of subjects: 119
Study 34256735 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants assessed with symptom surveillance questionnaire
Number of subjects: 119
Study 34256735 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with persistent symptoms
Number of subjects: 119
Study 34256822 — intervention group
Group type: EXPERIMENTAL
Intervention: Central venous oxygen saturation monitoring
Number of subjects: 0
Study 34256967 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline recommendations for first- to nth-line treatment of target mental health symptoms.
Number of subjects: 0
Study 34256967 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidance on addressing environmental factors and possible underlying diagnoses.
Number of subjects: 0
Study 34256967 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach to prescribing guidelines that incorporates real-world availability of treatments.
Number of subjects: 0
Study 34257421 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylmannosamine (ManNAc)
Number of subjects: 12
Study 34258059 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE IV
Number of subjects: 103
Study 34258059 — intervention group
Group type: COMPARATOR
Intervention: APACHE II
Number of subjects: 103
Study 34258383 — intervention group
Group type: EXPERIMENTAL
Intervention: Total plaque burden quantified by CCTA
Number of subjects: 125
Study 34258411 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperineal ultrasound (TPUS)
Number of subjects: 22
Study 34258507 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab after 12 months of denosumab
Number of subjects: 0
Study 34258507 — intervention group
Group type: COMPARATOR
Intervention: Denosumab
Number of subjects: 0
Study 34259012 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected ASD patients
Number of subjects: 38
Study 34259012 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 38
Study 34259020 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0
Study 34259039 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental Automated Whole-Breast Ultrasound
Number of subjects: 0
Study 34259164 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based psychotherapy plus treatment as usual (8 weeks)
Number of subjects: 60
Study 34259164 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual exclusively
Number of subjects: 60
Study 34259448 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratification for identification of Prognostic categories In the acute RESpiratory distress syndrome score
Number of subjects: 1301
Study 34259588 — intervention group
Group type: EXPERIMENTAL
Intervention: Floodlight Proof-of-Concept (PoC) app
Number of subjects: 76
Study 34259655 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone-positioning during ECMO
Number of subjects: 298
Study 34259655 — intervention group
Group type: COMPARATOR
Intervention: No prone-positioning during ECMO
Number of subjects: 298
Study 34259664 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (gas flow 0; 30-60 L/min)
Number of subjects: 10
Study 34259664 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (decreasing respiratory rate)
Number of subjects: 10
Study 34259664 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (mouth closed)
Number of subjects: 10
Study 34259664 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (various conditions)
Number of subjects: 10
Study 34259664 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-of-flight camera (RRTOF)
Number of subjects: 10
Study 34259921 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning risk score model for mortality prediction
Number of subjects: 3683
Study 34259921 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning risk score model
Number of subjects: 3683
Study 34259915 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankylosing spondylitis patients (Group 1)
Number of subjects: 60
Study 34260044 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriasis Symptoms and Impacts Measure (P-SIM)
Number of subjects: 1002
Study 34260044 — intervention group
Group type: EXPERIMENTAL
Intervention: P-SIM
Number of subjects: 1002
Study 34260061 — intervention group
Group type: EXPERIMENTAL
Intervention: Right supraclavicular fossa ultrasound view used for guidewire positioning
Number of subjects: 103
Study 34260061 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidewire J-tip positioning
Number of subjects: 103
Study 34260061 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance for correcting misplaced guidewires
Number of subjects: 103
Study 34260435 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral Hearing Aids (BiHA)
Number of subjects: 56
Study 34260435 — intervention group
Group type: COMPARATOR
Intervention: Bilateral Cochlear Implants (BiCI)
Number of subjects: 56
Study 34260480 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory Syncytial Virus (RSV) positive test
Number of subjects: 225
Study 34260480 — intervention group
Group type: COMPARATOR
Intervention: Influenza
Number of subjects: 225
Study 34260480 — intervention group
Group type: COMPARATOR
Intervention: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Number of subjects: 225
Study 34260706 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF tTau
Number of subjects: 32
Study 34260706 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF pTau
Number of subjects: 32
Study 34260706 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF NfL
Number of subjects: 32
Study 34260706 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF Ab42/40-ratio
Number of subjects: 32
Study 34260706 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF NfL (sensitivity analysis excluding spinal cord ischemia)
Number of subjects: 32
Study 34260823 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week pulmonary telerehabilitation programme including online training for 2 weeks and offline self-managed rehabilitation for 6 weeks.
Number of subjects: 0
Study 34260835 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-learning models and a natural-language model applied to decode speech from cortical activity.
Number of subjects: 1
Study 34260994 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear conditioning and extinction task during fMRI
Number of subjects: 76
Study 34261044 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 7
Study 34261348 — intervention group
Group type: EXPERIMENTAL
Intervention: CamAPS FX closed-loop system
Number of subjects: 18
Study 34261508 — intervention group
Group type: EXPERIMENTAL
Intervention: E-MOTIVE bundle (1) Early PPH detection using a calibrated drape, (2) uterine Massage, (3) Oxytocic drugs, (4) Tranexamic acid, (5) Intra Venous fluids, (6) genital tract Examination and escalation when necessary.
Number of subjects: 0
Study 34261638 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-processed food intake (≥5 servings/day)
Number of subjects: 116087
Study 34261638 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-processed food intake (1-4 servings/day)
Number of subjects: 116087
Study 34261638 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft drinks, refined sweetened foods, salty snacks, processed meat (subgroups of ultra-processed food)
Number of subjects: 116087
Study 34261638 — intervention group
Group type: COMPARATOR
Intervention: Intakes of white meat, red meat, dairy, starch, fruit, vegetables, and legumes
Number of subjects: 116087
Study 34261680 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative methods (observation, semistructured interviews, focus groups) and quantitative method (retrospective cohort)
Number of subjects: 0
Study 34261680 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative data analysis using thematic analysis derived from a grounded theory approach
Number of subjects: 0
Study 34261680 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative data analysis using descriptive statistics
Number of subjects: 0
Study 34261684 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Frailty Index (eFI) derived from electronic health records (EHR) data
Number of subjects: 1000
Study 34261684 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-based clinical Frailty Instrument
Number of subjects: 1000
Study 34261689 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support and rehabilitation for COVID-19 survivors
Number of subjects: 549
Study 34261767 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment (NSPT)
Number of subjects: 20
Study 34261794 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (HSCT) without myeloablation
Number of subjects: 9
Study 34261794 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmortem examination of a child with γc-SCID after HSCT
Number of subjects: 9
Study 34261794 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation of tertiary lymphoid organs
Number of subjects: 9
Study 34261794 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of RAR-related orphan receptor-positive LTi cells
Number of subjects: 9
Study 34261955 — intervention group
Group type: EXPERIMENTAL
Intervention: mPESS at least 5 (high probability of severe periodontitis)
Number of subjects: 32285
Study 34261955 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonreplaced missing teeth
Number of subjects: 32285
Study 34261955 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular annual visit to the dentist
Number of subjects: 32285
Study 34261986 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-piece monofocal hydrophobic acrylic intraocular lens (IOL) with hydroxyethyl methacrylate (HEMA)
Number of subjects: 384
Study 34261986 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated preloaded delivery system
Number of subjects: 384
Study 34262299 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI 100/62.5/25mcg (Group 1)
Number of subjects: 111
Study 34262299 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI 200/62.5/25mcg (Group 2)
Number of subjects: 111
Study 34262299 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-up group (from Group 1 to 200/62.5/25mcg)
Number of subjects: 111
Study 34262299 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI (both groups)
Number of subjects: 111
Study 34262403 — intervention group
Group type: EXPERIMENTAL
Intervention: Dydrogesterone 10 mg twice daily orally for 21 days (day 5-25 of each menstrual cycle) for 4 cycles
Number of subjects: 52
Study 34262403 — intervention group
Group type: EXPERIMENTAL
Intervention: Dydrogesterone
Number of subjects: 52
Study 34262514 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)-based preventive group intervention: EMOTION
Number of subjects: 0
Study 34262694 — intervention group
Group type: EXPERIMENTAL
Intervention: Transepidermal water loss (TEWL)
Number of subjects: 418
Study 34262694 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratum corneum hydration (SCH)
Number of subjects: 418
Study 34262694 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin pH
Number of subjects: 418
Study 34262694 — intervention group
Group type: EXPERIMENTAL
Intervention: Sebum content
Number of subjects: 418
Study 34262758 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised 24-week cardiovascular and resistance exercise intervention
Number of subjects: 22
Study 34263020 — intervention group
Group type: EXPERIMENTAL
Intervention: PR-T 0.2 mg/kg/d (Arm 1)
Number of subjects: 856
Study 34263020 — intervention group
Group type: EXPERIMENTAL
Intervention: PR-T 0.15-0.175 mg/kg/d plus basiliximab (Arm 2)
Number of subjects: 856
Study 34263020 — intervention group
Group type: EXPERIMENTAL
Intervention: PR-T 0.2 mg/kg/d delayed until day 5 posttransplant plus basiliximab (Arm 3)
Number of subjects: 856
Study 34263020 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 856
Study 34263020 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated glomerular filtration rate
Number of subjects: 856
Study 34263213 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (n=30), applied three times a week for the first 2 weeks
Number of subjects: 86
Study 34263213 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation exercise (n=28), applied three times a week for the first 2 weeks
Number of subjects: 86
Study 34263213 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=28), no intervention
Number of subjects: 86
Study 34263236 — intervention group
Group type: EXPERIMENTAL
Intervention: TEMpEST-Transitional Care Model Stroke Turkey interventions including at least 3 face-to-face interviews at the hospital, distance education via web, and telephone communications for 3 months, and 1 home visit within 7 days of discharge
Number of subjects: 70
Study 34263236 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 70
Study 34263302 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified MIRPE technique for surgical correction of pectus excavatum (PE)
Number of subjects: 47
Study 34263665 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Number of subjects: 0
Study 34263665 — intervention group
Group type: COMPARATOR
Intervention: Control group (previous treatments)
Number of subjects: 0
Study 34263701 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolic protection devices (EPDs) during TAVR procedures
Number of subjects: 0
Study 34263701 — intervention group
Group type: COMPARATOR
Intervention: No embolic protection devices (EPDs) during TAVR procedures
Number of subjects: 0
Study 34263738 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombomodulin
Number of subjects: 311
Study 34263738 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2, IL-10, IL-22, CXCL10, Fas-ligand, MMP9
Number of subjects: 311
Study 34263738 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte CSF (G-CSF), S100A8, IL-6
Number of subjects: 311
Study 34264412 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3076226 at doses ranging from 0.2-5.0 mg/kg as an intravenous infusion on Day 1 of each 21-day cycle.
Number of subjects: 25
Study 34264732 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated cannabis and anxiety reduction treatment (ICART)
Number of subjects: 0
Study 34264732 — intervention group
Group type: COMPARATOR
Intervention: MET-CBT alone
Number of subjects: 0
Study 34264743 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of plasma BCAAs
Number of subjects: 19472
Study 34264743 — intervention group
Group type: COMPARATOR
Intervention: Lowest quartile of plasma BCAAs
Number of subjects: 19472
Study 34264864 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled human malaria infection (CHMI) with 3.2 × 10^3 Plasmodium falciparum sporozoites
Number of subjects: 161
Study 34264864 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled human malaria infection (CHMI)
Number of subjects: 161
Study 34264865 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg oral methylphenidate
Number of subjects: 32
Study 34264865 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher D1R availability in caudate
Number of subjects: 32
Study 34264865 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher D2/3R availability in nucleus accumbens (NAc)
Number of subjects: 32
Study 34264973 — intervention group
Group type: EXPERIMENTAL
Intervention: Storytelling intervention group
Number of subjects: 96
Study 34264973 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 96
Study 34264973 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health workers
Number of subjects: 96
Study 34264973 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care workers
Number of subjects: 96
Study 34265048 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-valent HPV (9vHPV) vaccine types
Number of subjects: 1399
Study 34265151 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic 3D funnel-shaped intraperitoneal mesh
Number of subjects: 76